

Product Introduction

Aliskiren Hemifumarate

Aliskiren hemifumarate is a direct renin inhibitor with IC50 of 1.5 nM.

Technical Data:

Molecular Weight (MW):	609.83	
Formula:	C ₃₀ H ₅₃ N ₃ O ₆ .1/2C ₄ H ₄ O ₄	
Solubility (25°C)	DMSO 100 mg/mL	
* <1 mg/ml means slightly	Water 100 mg/mL	
soluble or insoluble:	Ethanol 100 mg/mL	
Purity:	>98%	
Storage:	3 years -20°C Powder	
	6 months-80°Cin DMSO	
CAS No.:	173334-58-2	

Biological Activity

Aliskiren hemifumarate appears to bind to both the hydrophobic S1/S3-binding pocket and to a large, distinct subpocket that extends from the S3-binding site towards the hydrophobic core of renin. Oral bioavailability of Aliskiren hemifumarate is 2.4% in rats, 16% in marmosets and about 2.5% in humans. [2] Aliskiren hemifumarate (< 10 mg/kg, oral) inhibits plasma renin activity and lowers blood pressure in sodium-depleted marmosets. [3] Once-daily oral treatment with Aliskiren hemifumarate lowers blood pressure effectively, with a safety and tolerability profile, in patients with mild-to-moderate hypertension. [4]

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

References

- [1] Nakamura Y, et al. ACS Med Chem Lett, 2012, 3(9), 754-758.
- [2] Buczko W, et al. Pharmacol Rep, 2008, 60(5), 623-631.
- [3] Wood JM, et al. Biochem Biophys Res Commun, 2003, 308(4), 698-705.
- [4] Gradman AH, et al. Circulation, 2005, 111(8), 1012-1018.
- [5] Oparil S, et al. Lancet, 2007, 370(9583), 221-229.



Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

